As the example may serve tumor necrosis factor (TNF)-α inhibition that is responsible for worsening of the heart function in patients with congestive heart failure, lipid profile disturbances as the result of interleukin (IL)-6 inhibition, or increased risk of thromboembolism in the course of JAK inhibitor administration. Here, TNF is linked to congestive heart failure.